BACE1 and Alzheimer disease: Thus, the identification of the molecular mechanism (s) (e.g. GGA3 depletion) responsible for BACE1 elevation may lead to the identification of BACE1 lowering strategies that can represent an attractive alternative to BACE inhibition for the prevention/treatment of AD.